Lunatus is a well-established company with over 20 years of experience representing international healthcare companies in the region, including Abbott Diagnostics and Boston Scientific. The company has a proven track record of successfully introducing and developing profitable pharmaceutical and medical technology brands. Lunatus collaborates with more than 40 global companies and offers a portfolio of 300 product lines.

"This LOI is an important step in our international growth strategy. We see strong potential for Zeqmelit® in the region. Lunatus is a strategic partner, thanks to its strong presence and proven market expertise," says Jonas Jönmark, CEO of AcuCort.

The parties now intend to finalise negotiations for a commercial agreement during 2025. The objective is to establish Zeqmelit® in several key markets across the region.

About Lunatus
Founded in 2003, Lunatus has formed multiple partnerships with international pharmaceutical companies. The company has a strong track record of successfully launching, building, and maintaining profitable brands.
www.lunatus.com

For further information: 
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.